News & Updates
Showing Oncology articles
Showing
Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC
Adding low-dose pembrolizumab to chemotherapy results in significant improvements in overall (OS) and progression-free survival (PFS) among patients with advanced non-small cell lung cancer (NSCLC), as shown in a phase 3 trial presented at ASCO 2026.
PROTEUS sets new course for prostate cancer
In the final analysis of the phase III PROTEUS trial, perioperative apalutamide + androgen deprivation therapy (APA+ADT) improves the curative success of radical prostatectomy (RP) in men with high-risk localized or locally advanced prostate cancer (HR LPC/LAPC).
Heavy alcohol consumption raises CRC risk
Individuals with high alcohol consumption are at increased risk of colorectal cancer (CRC), reports a study, which shows that alcohol intake may trigger colorectal carcinogenesis through mechanisms operating across major molecular pathways for CRC.
Daraxonrasib makes history in one of the deadliest cancers
Daraxonrasib—an oral, potent RAS(ON) multi-selective, tri-complex inhibitor—demonstrates unprecedented survival benefits in individuals with previously treated metastatic pancreatic adenocarcinoma (mPDAC) in the landmark phase III RASolute 302 study.
Cabozantinib plus nivolumab, ipilimumab improves PFS in advanced renal cell carcinoma
Adding cabozantinib to nivolumab and ipilimumab as first-line therapy, compared with placebo, results in prolonged progression-free survival (PFS) among untreated patients with advanced renal cell carcinoma (RCC), with no new safety signals seen, as shown by the results of the phase III COSMIC-313 study.
